Flecainide (Acetate)
Flecainide (Acetate) Information

About Flecainide (Acetate)

Flecainide (Acetate) fluorinated benzamine. Flecainide (Acetate) is a potent sodium channel and potassium channel blocking agent. Flecainide (Acetate) maintains normal heart rate and is used to treat irregular heart rhythms (arrhythmias).

Indications

Flecainide (Acetate) is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Ventricular arrhythmias, Ventricular fibrillation, and can also be given in adjunctive therapy as an alternative drug of choice in Angina, Blood Pressure.

Contraindication

Flecainide (Acetate) is contraindicated in conditions like Cardiogenic shock,Cardiac failure,Conduction system disease.

Side Effects

Flecainide (Acetate) produces potentially life-threatening effects which include Conduction system disorders, Heart failure, Ventricular proarrhythmic effects. which are responsible for the discontinuation of Flecainide (Acetate) therapy.The signs and symptoms that are produced after the acute overdosage of Flecainide (Acetate) include Asystole, Respiratory paralysis.The symptomatic adverse reactions produced by Flecainide (Acetate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Ataxia, Nausea, Anxiety, Light-headedness, Blurred vision, Metallic taste, Ataxia.

Warnings

Patients with pacemakers (especially those who may be pacemaker dependent because stimulation threshold may rise appreciably); avoid in sinus node dysfunction, atrial conduction defects, second-degree or greater AV block, bundle branch block or distal block unless pacing rescue available; atrial fibrillation following heart surgery; elderly (accumulation may occur); hepatic impairment; renal impairment (monitor plasma-flecainide concentration); pregnancy; breast-feeding.

High Risk Groups

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.